Andreas Wolf

TL;DR: The clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells, is reported on.

TL;DR: In this article, the UHV multichamber photoelectron gun was used to study the removal of surface pollutants and the degraded (Cs,O)-activation layer during the cleaning procedure.

TL;DR: In this phase I study of relapsed/refractory NHL, continuous infusion with CD19-targeted immunotherapy blinatumomab at various doses and schedules was feasible, with an MTD of 60 μg/m(2)/day that showed antilymphoma activity.

TL;DR: The binding domains of cetuximab and pantitumumab are used for constructing T cell-engaging BiTE antibodies that prevented at very low doses growth of tumors from KRAS- and BRAF-mutated human CRC xenografts, whereas cetUXimab was not effective.

TL;DR: It is demonstrated that CD56-positive lymphocytes within human PBMC contributed >90% to ADCC and that normal serum levels of IgG effectively competed for in vitro binding of an IgG1 antibody to low-affinity Fcgamma receptor type III (CD16), as is present on natural killer (NK) cells.